Instead, the ADA-EASD recommends the preferential use of GLP-1 receptor agonists, SGLT2 inhibitors, and some DPP-4 inhibitors after initial metformin monotherapy for T2D patients with established atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease (CKD), and patients who need to minimize hypoglycemia and/or body weight-related problems (Figure 1) [10]. This evidence concerns the gene SLC5A2 and chronic kidney disease.